New Drugs of 2011, Part 2

Michael A. Mancano, PharmD
Published Online: Wednesday, March 14, 2012
Follow Pharmacy_Times:

Pharmacy Times Office of Continuing Professional Education


New Drugs of 2011, Part 2

Michael A. Mancano, PharmD

Clinical Professor of Pharmacy Practice

Interim Chair, Department of Pharmacy Practice

Temple University School of Pharmacy; Philadelphia, PA

Clinical Consultant, Department of Pharmacy

Pennsylvania Hospital; Philadelphia, PA


Michael A. Mancano, PharmD, has no relevant affiliations or financial relationships to disclose.

Judy V. Lum, MPA; Ann C. Lichti, CCMEP; and Donna Fausak of the Pharmacy Times Office of Continuing Professional Education have no relevant affiliations or financial relationships to disclose related to this activity.


Educational Objectives

Upon completing the program, participants should be able to:

  1. Discuss the clinical indications of 8 new drugs approved by the FDA in 2011.
  2. Explain the mechanisms of action of the drugs discussed within this program.
  3. Recognize the clinically relevant drug interactions for the drugs reviewed in this program.
  4. Identify the most common adverse reactions for the discussed new drug approvals.
  5. Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: February 10, 2012

Expiration date: February 10, 2014

Estimated time to complete activity: 2.0 hours

Fee: There is no charge for taking this course online.

Click here to view this activity.



Related Articles
Ludy L. Underwood, Cardinal Health sales manager for retail/alternative care, pharmaceutical division, talks about how health information technology has changed the business of pharmacy.
When California Health Sciences University was founded in 2012, the very first program offered was the College of Pharmacy due to high demand for pharmacists in the Central Valley area.
Pharmacies can anticipate new, specific goals that tie fee-for-service Medicare payments to value-based payment models, according to the US Department of Health and Human Services (HHS).
A common thread across all US Centers for Medicare and Medicaid Services programs is a shift of risk off of CMS and onto health care providers, according to Sam Stolpe, PharmD, senior director of Quality Strategies and Business Development at Pharmacy Quality Alliance.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$